ReviewDrugs & aging2012
Off-label prescribing in older patients.
Review in Drugs & aging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Thematic mapping of off-label prescription in psychiatry and its implications for bioethics, human rights, and clinical practice: a scoping review.Frontiers in psychiatry · 2026Pooled it
- Medication management for people with dementia in primary care: description of implementation in the DelpHi study.BMC geriatrics · 2013Trial
- Incorporating pharmacokinetic data into personalised prescribing for older people: challenges and opportunities.European geriatric medicine · 2021Review
- Mapping of drug-related problems among older adults conciliating medical and pharmaceutical approaches.European geriatric medicine · 2021Review
- Translating evidence into practice during the COVID-19 pandemic: pitfalls and mileages.Therapeutic advances in drug safety · 2021Article
- Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems.Therapeutics and clinical risk management · 2021Article
- Under-representation of elderly in clinical trials: An analysis of the initial approval documents in the Food and Drug Administration database.British journal of clinical pharmacology · 2019Article
- Psychotropic medicine utilization in older people in New Zealand from 2005 to 2013.Drugs & aging · 2014Article
- Identifying knowledge gaps in the labeling of medications for geriatric patients.P & T : a peer-reviewed journal for formulary management · 2013Article
- Off-label prescribing in older people: the need for increased awareness and caution.Drugs & aging · 2012Article
- Optimizing pharmacotherapy in older patients: a European perspective.Drugs & aging · 2012Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The practice of off-label prescribing, i.e. prescribing drugs either for unregistered/unapproved therapeutic indications and age groups or using unregistered/unapproved doses or methods of administration, is common in older patients. This may be due to the poor representation of this group in pre-marketing clinical trials assessing therapeutic efficacy and safety of novel therapies or merely to the fact that trials in a particular indication have not been undertaken. Off-label prescribing should not be viewed as scientifically or ethically unsound when there are good clinical data to support a particular therapeutic indication. However, a number of steps should be followed in order to ensure therapeutic efficacy, reducing, at the same time, the risk of adverse drug reactions and/or medical litigation. This article discusses the current epidemiology and trends in off-label prescribing in older patients, the scientific and ethical justification of this practice, medico-legal implications, and proposed strategies for risk mitigation.
Indexed as
Identifiers
22642777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.